Quarterly report pursuant to Section 13 or 15(d)

License and Collaboration Agreements, BioSense License and Assignment Agreement (Details)

v3.23.1
License and Collaboration Agreements, BioSense License and Assignment Agreement (Details)
3 Months Ended 12 Months Ended
Mar. 10, 2020
USD ($)
Mar. 31, 2023
USD ($)
Milestone
Country
Dec. 31, 2021
USD ($)
BioSense License and Assignments Agreement [Member]      
Collaboration and License Agreement [Abstract]      
Non-refundable cash payment received $ 1,650,000    
Milestone payment achieved for performance obligation, recorded as collaboration revenue     $ 100,000
Maximum amount of payments receivable for development, regulatory and commercial milestones   $ 84,500,000  
Milestone payments received   0  
BioSense License and Assignments Agreement [Member] | Rexahn [Member]      
Collaboration and License Agreement [Abstract]      
Non-refundable cash payment received $ 1,550,000    
Processa License Agreement [Member]      
Collaboration and License Agreement [Abstract]      
Milestone payments received   $ 0  
Number of times sales milestone payments | Milestone   1  
Percentage of milestone payments eligible to receive on sub-license agreement   32.00%  
Number of countries | Country   1  
Milestone period to administer drug clinical trial of licensed product on first patient   3 years  
Milestone period to administer drug clinical trial of licensed product on first patient for second indication   5 years  
Period of opportunity to cure breach of agreement   120 days  
Period of prior written notice to be served for termination of agreements   120 days